Problems with risk-sharing study must not deter future collaborations
This article was originally published in Scrip
Executive Summary
“A costly failure” and “a fiasco” are just two of the epithets that have been used to describe the UK’s first-ever risk-sharing scheme to evaluate the long-term cost-effectiveness of two multiple sclerosis therapies, β-interferon and glatiramer acetate. Or as one commentator put it: “This may well be the most expensive publicly-funded ongoing health-related study in the UK, and probably anywhere, ever.”